About the Study
This study is looking to see if the study drug, is safe, effective, and well tolerated for preventing menstrual migraines when taken for 7 days in row starting 3 days before the start of your period. The study drug is currently approved to treat other medical conditions and is now being studied for menstrual migraine.
If you qualify and choose to participate, there is a 50% chance you will receive the study drug and a 50% chance you will receive a placebo. A placebo is an inactive material that looks like study drug but does not contain any active ingredient.
You will be on this study for about 84 weeks which will include a screening period, a treatment period, and an open-label extension period. The study will require up to 13 in-clinic visits. If you qualify and choose to participate, you may be compensated for your study-related time and travel. Your participation is entirely voluntary, and you can leave the study at any time.